{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-200597","form_type":"8-K","ticker":"XAGE","cik":"0001842939","company_name":"Longevity Health Holdings, Inc.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.678214+00:00","generated_at":"2026-06-12T19:03:35.306261+00:00","sec_items":["1.01","3.02","5.03","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Carmell Corp to acquire Axolotl Biologix for up to $140M; Axolotl TTM rev $50M, EBITDA $5M","bullets":["Axolotl had unaudited TTM revenue ~$50M and TTM EBITDA ~$5M as of June 30, 2023.","Initial consideration: $8M cash + $57M in CTCX stock ($65M total), plus up to $75M in milestone payments.","Axolotl's human amnion allografts are FDA-compliant; two products added to CMS Part B pricing in Q2 2023.","Transaction expected to close in Q3 2023; Axolotl shareholders subject to 12-month lock-up.","Company changes name to Carmell Corporation; Axolotl CEO Josh Sandberg becomes Strategic Advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-200597","json":"https://secwatch.observer/filing/0001193125-23-200597.json","markdown":"https://secwatch.observer/filing/0001193125-23-200597.md","text":"https://secwatch.observer/filing/0001193125-23-200597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/0001193125-23-200597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/d525835d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T19:03:35.306261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"562afd9888e6107a023cbb995aae79ab9f6c2fb4","claim":"Longevity Health Holdings, Inc.: Company renamed from Carmell Therapeutics Corporation to Carmell Corporation (effective 2023-08-01).","evidence_excerpt":"On August 1, 2023, the board of directors of the Company approved and adopted an amendment (the “ Charter Amendment ”) to the Company’s existing amended and restated certificate of incorporation to change the name of the Company from “Carmell Therapeutics Corporation” to “Carmell Corporation.”","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/0001193125-23-200597-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-08-01"}],"fact_type":"governance_change"},{"claim_id":"6ce132f1f150ed87d3af51b28bc84b468107b7a3","claim":"Longevity Health Holdings, Inc. entered into Agreement and Plan of Merger with Axolotl Biologix, Inc. valued at up to approximately $8.0 million in cash, a number of shares of the Company’s common stock equal to (effective 2023-07-26).","evidence_excerpt":"On July 26, 2023, Carmell Corporation (formerly Carmell Therapeutics Corporation) (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Aztec Merger Sub, Inc. (“ Merger Sub ”) and Axolotl Biologix, Inc. (“ Axolotl ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/0001193125-23-200597-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Axolotl Biologix, Inc."},{"label":"Value","value":"up to approximately $8.0 million in cash, a number of shares of the Company’s common stock equal to"},{"label":"Effective","value":"2023-07-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}